tiprankstipranks
Lung Kee (Bermuda) Holdings Limited (HK:0255)
:0255
Hong Kong Market
Want to see HK:0255 full AI Analyst Report?

Lung Kee (Bermuda) Holdings Limited (0255) AI Stock Analysis

2 Followers

Top Page

HK:0255

Lung Kee (Bermuda) Holdings Limited

(0255)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
HK$1.50
▼(-9.09% Downside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by mixed financial performance: a very strong, low-leverage balance sheet and generally positive cash generation offset by persistent net losses and contracting revenue. Technicals add modest support with improving short-to-medium trend and neutral momentum, while valuation benefits from the high dividend yield but is tempered by the negative P/E tied to ongoing losses.
Positive Factors
Strong balance sheet (low leverage)
Extremely low leverage gives the company durable financial flexibility: it lowers solvency risk, preserves borrowing capacity, and allows management to fund operations, capex or working-capital needs while executing turnaround measures over the next several months.
Negative Factors
Three years of net losses
Sustained net losses erode retained earnings and limit financial options: they can constrain reinvestment, pressure dividend sustainability, and force cost-cutting or asset sales if profitability isn't restored within a medium-term horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet (low leverage)
Extremely low leverage gives the company durable financial flexibility: it lowers solvency risk, preserves borrowing capacity, and allows management to fund operations, capex or working-capital needs while executing turnaround measures over the next several months.
Read all positive factors

Lung Kee (Bermuda) Holdings Limited (0255) vs. iShares MSCI Hong Kong ETF (EWH)

Lung Kee (Bermuda) Holdings Limited Business Overview & Revenue Model

Company Description
Lung Kee Group Holdings Limited, an investment holding company, manufactures and markets mould bases and related products in the People's Republic of China and internationally. The company also engages in the property investment and corporate mana...
How the Company Makes Money
The company primarily makes money by selling mould bases and related standard mould components to mould makers and manufacturers that require these parts as inputs for producing injection moulds and die-casting moulds. Revenue is generally generat...

Lung Kee (Bermuda) Holdings Limited Financial Statement Overview

Summary
Overall financials are mixed: the income statement is weak with three straight years of net losses and renewed revenue contraction in 2025, but the balance sheet is a major strength with extremely low leverage, and cash flow remains relatively resilient with positive operating cash flow and positive free cash flow in 2024–2025 despite some historical inconsistency.
Income Statement
38
Negative
Balance Sheet
82
Very Positive
Cash Flow
66
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.20B1.32B1.55B1.45B1.60B2.27B
Gross Profit210.41M268.35M951.69M263.90M398.00M777.07M
EBITDA85.80M108.90M148.58M56.87M180.74M472.05M
Net Income-29.43M-22.62M-13.67M-72.43M15.81M227.84M
Balance Sheet
Total Assets1.76B1.82B1.97B2.09B2.30B2.75B
Cash, Cash Equivalents and Short-Term Investments649.71M588.63M546.65M428.76M536.64M833.59M
Total Debt2.79M4.36M7.83M6.57M9.56M9.02M
Total Liabilities249.92M266.93M298.08M294.22M314.90M474.46M
Stockholders Equity1.51B1.55B1.67B1.80B1.99B2.27B
Cash Flow
Free Cash Flow221.06M173.25M190.82M-35.72M-93.17M168.61M
Operating Cash Flow257.50M213.28M226.34M77.21M89.17M369.94M
Investing Cash Flow-16.31M-27.03M-24.35M-98.07M-170.05M-193.03M
Financing Cash Flow-128.00M-165.69M-67.33M-73.86M-168.90M-277.76M

Lung Kee (Bermuda) Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.65
Price Trends
50DMA
1.38
Positive
100DMA
1.36
Positive
200DMA
1.37
Positive
Market Momentum
MACD
<0.01
Negative
RSI
61.33
Neutral
STOCH
-40.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0255, the sentiment is Positive. The current price of 1.65 is above the 20-day moving average (MA) of 1.40, above the 50-day MA of 1.38, and above the 200-day MA of 1.37, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.33 is Neutral, neither overbought nor oversold. The STOCH value of -40.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0255.

Lung Kee (Bermuda) Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
HK$1.97B24.1013.60%0.40%37.42%124.96%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
63
Neutral
HK$893.95M-30.32-1.92%14.13%-17.65%-538.68%
62
Neutral
HK$1.30B5.237.26%5.69%-4.88%-0.62%
54
Neutral
HK$1.39B86.886.05%-31.18%-121.38%
47
Neutral
HK$299.41M-6.90-3.69%4.95%>-0.01%15.55%
47
Neutral
HK$547.17M47.270.61%5.28%23.21%11.11%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0255
Lung Kee (Bermuda) Holdings Limited
1.42
-0.01
-1.05%
HK:0822
Ka Shui International Holdings Limited
0.34
-0.01
-4.29%
HK:0838
Eva Precision Industrial Holdings Limited
0.75
-0.28
-27.17%
HK:0929
IPE Group Limited
0.53
-0.03
-5.02%
HK:3816
KFM Kingdom Holdings Ltd.
3.58
3.19
820.31%
HK:2535
WK Group (Holdings) Limited
0.70
0.13
22.81%

Lung Kee (Bermuda) Holdings Limited Corporate Events

Lung Kee Group Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 6, 2026
Lung Kee Group Holdings Limited has scheduled a board meeting for 21 August 2026 in Hong Kong to review and approve the group&#8217;s interim results for the six months ended 30 June 2026. The board will also consider the payment of an interim div...
Lung Kee Group Updates Bermuda Registered Office Address
Jul 20, 2026
Lung Kee Group Holdings Limited has announced a change to the address of its registered office in Bermuda, effective 3 August 2026, relocating to Richmond House on Par-la-Ville Road in Hamilton. The company confirmed that its branch share registra...
Lung Kee Shareholders Approve All AGM Resolutions, Endorse Dividend and Capital Mandates
May 18, 2026
Lung Kee Group Holdings Limited reported that shareholders approved all resolutions at its 18 May 2026 annual general meeting, including adoption of the 2025 audited financial statements and a final dividend of HK12 cents per share. The meeting sa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 04, 2026